HK Stock Market Move | INNOVENT BIO (01801) rose more than 5% AI technology drives the development of the pharmaceutical sector China Securities expected it to turn blue.

INNOVENT BIO (01801) rose by more than 5%, reaching a 5.34% increase as of the time of this report, with shares at 41.4 Hong Kong dollars and a trading volume of 673 million Hong Kong dollars. On the news front, BOCOM INTL recently pointed out in a research report that AI technology is driving the development of the pharmaceutical sector, bringing new opportunities. They suggest investors to pay attention to innovative AI-related technologies and the valuation recovery opportunities they bring. The bank noted that several pharmaceutical companies, including INNOVENT BIO, have announced that they have connected or will connect to DeepSeek. The expected acceleration of AI+ healthcare landing is expected to help companies improve pharmaceutical research and development efficiency, optimize drug design, and bring positive effects for CROs and innovative drug companies. It is worth noting that after the market closes today, the Hang Seng Index Company will announce the results of the half-year review of the Hang Seng series of indices. According to previous estimates by CICC, in terms of Hang Seng Index adjustments, companies like INNOVENT BIO are among the potential candidates that may be included in the list. It is reported that INNOVENT BIO achieved total product revenues of over 8.2 billion yuan in 2024, maintaining a growth of over 40% year-on-year. In the fourth quarter of 2024, the company's total product revenues exceeded 2 billion yuan, with a year-on-year growth of over 25%.